Short answer: In 2019 the FDA stated Vinpocetine does not meet the statutory definition of a dietary ingredient and specifically warned pregnant women against consuming it.
Why this regulatory nuance is explained carefully, not glossed over
The FDA has not banned it — a direct, important clarification distinguishing an unresolved regulatory question from an outright prohibition.
What genuine research supports this ingredient despite the concern
European clinical trials at prescription doses show modest improvements in cerebral blood flow — Vinpocetine is a prescription medication in parts of Europe, worth understanding alongside its unsettled US status.
⚠️ Worth knowing: the unsettled regulatory picture is a legitimate consideration when choosing among nootropic products — a fair, balanced framing.